Relugolix Completed Phase 2 Trials for Prostate Cancer Treatment

IndicationsStatusPurposePhase
CompletedTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT02083185A Phase 2 Study to Evaluate the Safety and Efficacy of TAK-385, Together With a Leuprorelin Observational Cohort, in Participants With Prostate Cancer
NCT02135445Safety and Efficacy of TAK-385 for Patients With Localized Prostate Cancer